Navigation Links
Discovery Labs Appoints John R. Leone to Board of Directors

WARRINGTON, Pa., Nov. 14, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced it has appointed John R. Leone to the Company's Board of Directors, effective immediately.

"With over three decades of experience and an outstanding track record in pharmaceutical operations, commercial portfolio management, and financing life science companies, John's expertise will be invaluable to our Board," said W. Thomas Amick, Chairman of the Board and Chief Executive Offer at Discovery Labs, "As we prepare for the commercial launch of SURFAXIN® and continue the development of AEROSURF® and SURFAXIN LS™, John will bring an important perspective in guiding the business and financial strategies we employ as we build our Company."

Since 2007, Mr. Leone has been a Partner at Paul Capital Healthcare, a leading private equity firm that manages one of the largest dedicated healthcare funds globally.  At Paul Capital, Mr. Leone has focused on investment opportunities in commercial-stage life science companies.  From 2004 to 2006, Mr. Leone was President and Chief Executive Officer at Cambrex Corporation, a publicly-traded life sciences company providing innovative solutions that accelerate the development and commercialization of pharmaceutical products.  Previously, Mr. Leone served as Senior Vice President and Chief Operating Officer of U.S. Commercial Operations at Aventis Pharmaceuticals.  In this position he had responsibility for all commercial business units, including oncology, metabolism, cardiovascular, dermatology, respiratory and anti-infective.  Mr. Leone played a key role in spearheading the successful integration of its predecessor companies, Rhone-Poulenc Rorer and Hoechst Marion Roussel, to form Aventis.

"I am excited to join the Board to help guide and provide strategic input at this important juncture for the Company." said John R. Leone, "I am impressed with Discovery Labs' KL4 surfactant and aerosol delivery technologies and believe they have the potential to advance a new standard in respiratory critical care, beginning by addressing the unmet needs of premature infants at risk for respiratory distress syndrome (RDS).  I look forward to being a part of that change."

Mr. Leone's commercial experience also includes significant domestic and international executive management roles with Wyeth, where he held the following positions during his tenure: General Manager, Ayerst International; General Manager of commercial operations for Ayerst U.S.; Group Vice President of Wyeth International Marketing and General Manager, Vaccine and Pediatric Division.  Mr. Leone started his healthcare career at Pfizer Laboratories, where he held various senior marketing positions in both the U.S. and International groups and was responsible for the commercial launch of numerous pharmaceutical products.

Mr. Leone also serves on the Board of Directors at ViroPharma Incorporated.  Mr. Leone received his BS degree in Engineering from the U.S. Military Academy at West Point and his MBA from the University of Colorado.

Discovery Laboratories, Inc. is a specialty biotechnology company with one focus – to advance a new standard in respiratory critical care.  Discovery Labs' novel proprietary KL4 surfactant technology produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant and is being developed in liquid, lyophilized, and aerosolized dosage forms. Discovery Labs is also developing its proprietary drug delivery technologies to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs believes that its proprietary technologies make it possible, for the first time, to develop a significant pipeline of products to address a variety of respiratory diseases for which there frequently are few or no approved therapies.  For more information, please visit our website at

Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.  Examples of such risks and uncertainties, including those related to the potential commercial introduction of SURFAXIN and AFECTAIR and Discovery Labs' research and development programs are described in Discovery Labs' filings with the Securities and Exchange Commission, including the most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto.

SOURCE Discovery Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Aptuit Drug Discovery & Development Center In Verona, Italy Hits 100th Client Milestone
2. Del Mar CEO Delivers Keynote Address at International Drug Discovery Science and Technology Conference
3. Discovery Labs Reports Third Quarter 2012 Financial Results
4. BD Completes Sale of Majority of Discovery Labware Unit
5. Discovery of New "Youth Pill" Revealed At International Scientific Conference
6. Drug Discovery in Rare Diseases
7. ESTEVE Fosters R & D by Transferring its Center for Drug Discovery to the Science Park of Barcelona (PCB)
8. Initiating Rare Disease Drug Discovery Projects
9. Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
10. AstraZeneca And The Broad Institute Partner To Advance Discovery Of Antibacterial And Antiviral Agents
11. Drug Discovery Technologies, BCC Research
Post Your Comments:
(Date:12/1/2015)... December 1, 2015 --> ... research report "Nucleic Acid Labeling Market by Product (Reagents ... Random Primer, In Vitro Transcription, Reverse Transcription, End Labeling), ... MarketsandMarkets, The global market is expected to reach USD ... 2015, growing at a CAGR of 8.65%. ...
(Date:12/1/2015)... , Dec. 01, 2015 ... announced the addition of the ... Campylobacter, Cryptosporidium, E. Coli, Enterovirus, Rhinovirus, ... report to their offering. --> ... addition of the "2016 Europe ...
(Date:12/1/2015)... ANGELES , Dec. 1, 2015 CytRx ... development company specializing in oncology, today announced that it ... the company,s pivotal global Phase 3 clinical trial of ... (STS). Enrollment was originally estimated to be completed in Q1 ... being conducted under a Special Protocol Assessment from the ...
Breaking Medicine Technology:
(Date:12/1/2015)... , ... December 01, 2015 , ... ... of Excellence (BHCOE) today announced that the organization has awarded Education and Developmental ... with a Distinguished Award. The award celebrates exceptional special needs providers that excel ...
(Date:12/1/2015)... MA (PRWEB) , ... December 01, 2015 , ... Lutronic, ... release of Clarity, the latest addition to the devices for sale in the United ... 755 nm Alexandrite and long-pulsed 1064 nm Nd:YAG lasers, into a single platform that ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... XTC ... selected 10 semi-finalists to head to Las Vegas for CES 2016, the world’s largest ... CEO of Consumer Technology Association Gary Shapiro, Founding Partner of Pacific Investments Veronica Serra, ...
(Date:12/1/2015)... ... , ... Nurotron Biotechnology Co., Ltd., maker of cochlear implant systems, has won ... order will be from the China Disabled Persons’ Federation, a central government association, for ... for children and adults suffering from severe and profound hearing loss . The ...
(Date:12/1/2015)... IL (PRWEB) , ... December 01, 2015 , ... ... Unified Contact Center Enterprise Authorized Technology Provider (ATP) status from Cisco. This designation ... deploy and support Cisco Unified Contact Center solutions targeted to the high-end enterprise ...
Breaking Medicine News(10 mins):